Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Nie, Zhen Lin ^a   Pan, Yu Qin ^a   He, Bang Shun ^a   Gu, Ling ^b   Chen, Li Ping ^b   Li, Rui ^b   Xu, Ye Qiong ^a   Gao, Tian Yi ^a   Song, Guo Qi ^a   Hoffman, Andrew R ^c   Wang, Shu Kui ^a   Hu, Ji Fan ^c,d  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING NORMAL UNIVERSITY   (China)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Colorectal cancer; Genomic imprinting; IGF2; Oncolytic adenovirus; Targeted therapy

Indexed keywords

EARLY REGION 1A PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; MESSENGER RNA; ONCOLYTIC ADENOVIRUS; PLASMID VECTOR; PROTEIN; PROTEIN P53; SOMATOMEDIN B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER MODEL; CELL LINE; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; FEASIBILITY STUDY; GENE CONSTRUCT; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENE TARGETING; GENOME IMPRINTING; GES 1 CELL LINE; HCT 8 CELL LINE; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SURVIVAL; TUMOR CELL; TUMOR XENOGRAFT; VIRUS RECOMBINANT;

ADENOVIRUS E1A PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CLONING, MOLECULAR; COLORECTAL NEOPLASMS; FEMALE; GENETIC THERAPY; GENOMIC IMPRINTING; GREEN FLUORESCENT PROTEINS; HT29 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; KAPLAN-MEIER ESTIMATE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; HUMAN ADENOVIRUS; MUS;

EID: 84869222320     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-86     Document Type: Article

References (36)

1. World Health Organization The global burden of disease: 2004 update 2008, http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html, World Health Organization.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
3. Falls JG, Pulford DJ, Wylie AA, Jirtle RL. Genomic imprinting: implications for human disease. Am J Pathol 1999, 154:635-647. 10.1016/S0002-9440(10)65309-6, 1866410, 10079240.
4. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994, 369:414-418. 10.1038/369414a0, 7910953.
5. DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991, 64:849-859. 10.1016/0092-8674(91)90513-X, 1997210.
6. Chen HL, Li T, Qiu XW, Wu J, Ling JQ, Sun ZH, Wang W, Chen W, Hou A, Vu TH, Hoffman AR, Hu JF. Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming. EMBO J 2006, 25:5329-5338. 10.1038/sj.emboj.7601399, 1636609, 17082775.
7. Ling JQ, Li T, Hu JF, Vu TH, Chen HL, Qiu XW, Cherry AM, Hoffman AR. CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. Science 2006, 312:269-272. 10.1126/science.1123191, 16614224.
8. Phillips JE, Corces VG. CTCF: master weaver of the genome. Cell 2009, 137:1194-1211. 10.1016/j.cell.2009.06.001, 3040116, 19563753.
9. Li T, Hu JF, Qiu X, Ling J, Chen H, Wang S, Hou A, Vu TH, Hoffman AR. CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol Cell Biol 2008, 28:6473-6482. 10.1128/MCB.00204-08, 2577414, 18662993.
10. Zhang H, Niu B, Hu JF, Ge S, Wang H, Li T, Ling J, Steelman BN, Qian G, Hoffman AR. Interruption of intrachromosomal looping by CCCTC binding factor decoy proteins abrogates genomic imprinting of human insulin-like growth factor II. J Cell Biol 2011, 193:475-487. 10.1083/jcb.201101021, 3087012, 21536749.
11. Pan Y, He B, Li T, Zhu C, Zhang L, Wang B, Xu Y, Qu L, Hoffman AR, Wang S, Hu J. Targeted tumor gene therapy based on loss of IGF2 imprinting. Cancer Biol Ther 2010, 10:290-298. 10.4161/cbt.10.3.12442, 3040838, 20592487.
12. Breyer B, Jiang W, Cheng H, Zhou L, Paul R, Feng T, He TC. Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther 2001, 1:149-162. 10.2174/1566523013348689, 12108952.
13. Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist 2002, 7:46-59.
14. Ueno NT, Yu D, Hung MC. E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. Breast Cancer 2001, 8:285-293. 10.1007/BF02967526, 11791119.
15. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376. 10.1126/science.274.5286.373, 8832876.
16. Chakraborty AA, Tansey WP. Adenoviral E1A function through Myc. Cancer Res 2009, 69:6-9. 10.1158/0008-5472.CAN-08-3026, 19117980.
17. Turnell AS, Stewart GS, Grand RJ, Rookes SM, Martin A, Yamano H, Elledge SJ, Gallimore PH. The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression. Nature 2005, 438:690-695. 10.1038/nature04151, 16319895.
18. Cattaneo R. Paramyxovirus entry and targeted vectors for cancer therapy. PLoS Pathog 2010, 6:e1000973. 10.1371/journal.ppat.1000973, 2891830, 20585633.
19. Hammill AM, Conner J, Cripe TP. Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer 2010, 55:1253-1263. 10.1002/pbc.22724, 20734404.
20. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008, 25:462-466.
21. Jia W, Zhou Q. Viral vectors for cancer gene therapy: viral dissemination and tumor targeting. Curr Gene Ther 2005, 5:133-142. 10.2174/1566523052997460, 15638717.
22. Cao X, Yang M, Wei RC, Zeng Y, Gu JF, Huang WD, Yang DQ, Li HL, Ding M, Wei N, Zhang KJ, Xu B, Liu XR, Qian QJ, Liu XY. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Gene Ther 2011, 18:765-777. 10.1038/gt.2011.16, 21412282.
23. Wang H, Song X, Zhang H, Zhang J, Shen X, Zhou Y, Fan X, Dai L, Qian G, Hoffman AR, Hu JF, Ge S. Potentiation of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts. Int J Cancer 2012, 130:443-453. 10.1002/ijc.26013, 3118272, 21351100.
24. Raus S, Coin S, Monsurrò V. Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions. Korean J Hematol 2011, 46:229-238. 10.5045/kjh.2011.46.4.229, 3259514, 22259628.
25. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011, 8:12-28. 10.1021/mp100219n, 21126047.
26. Liikanen I, Monsurrò V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, Escutenaire S, Hemminki O, Dias JD, Cerullo V, Kanerva A, Pesonen S, Marzioni D, Colombatti M, Hemminki A. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther 2011, 19:1858-66.6. 10.1038/mt.2011.144, 3188743, 21792178.
27. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 1998, 4:1276-1280. 10.1038/3260, 9809551.
28. Nishihara S, Hayashida T, Mitsuya K, Schulz TC, Ikeguchi M, Kaibara N, Oshimura M. Multipoint imprinting analysis in sporadic colorectal cancers with and without microsatellite instability. Int J Oncol 2000, 17:317-322.
29. Takano Y, Shiota G, Kawasaki H. Analysis of genomic imprinting of insulin-like growth factor 2 in colorectal cancer. Oncology 2000, 59:210-216. 10.1159/000012163, 11053988.
30. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 2001, 1:525-538. 10.1517/14712598.1.3.525, 11727523.
31. Yu DC, Working P, Ando D. Selectively replicating oncolytic adenoviruses as cancer therapeutics. Curr Opin Mol Ther 2002, 4:435-443.
32. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 2002, 9:979-986. 10.1038/sj.cgt.7700539, 12522437.
33. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6:879-885. 10.1038/78638, 10932224.
34. Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002, 62:5736-5742.
35. Zhang H, Wang H, Zhang J, Qian G, Niu B, Fan X, Lu J, Hoffman AR, Hu JF, Ge S. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther 2009, 17:57-64. 10.1038/mt.2008.236, 2834989, 19018252.
36. Takeuchi A, Mishina Y, Miyaishi O, Kojima E, Hasegawa T, Isobe K. Heterozygosity with respect to Zfp148 causes complete loss of fetal germ cells during mouse embryogenesis. Nat Genet 2003, 33:172-176. 10.1038/ng1072, 12524542.